RecruitingPhase 4NCT05331911

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane


Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Enrollment

500 participants

Start Date

Apr 26, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma. The study will enroll approximately 500 volunteers to compare the progression-free or overall survival in patients undergoing elective partial hepatectomy for primary liver tumors between propofol and sevoflurane for the maintenance of anesthesia.


Eligibility

Min Age: 20 YearsMax Age: 80 Years

Inclusion Criteria3

  • Twenty to eighty-year-old.
  • ASA class I-III.
  • Patients undergoing partial hepatectomy for hepatocellular carcinoma under general anesthesia.

Exclusion Criteria12

  • Severe mental disorder
  • Pregnant or lactating women
  • Morbidly obese
  • Allergy to any of the drugs used in this study
  • Recurrent tumor or repeat surgery
  • Biopsy cases
  • Incomplete data collection before the surgery
  • Palliative treatment after surgery
  • simultaneous treatment of other malignancies
  • Combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine
  • Diagnosed as benign liver tumor
  • Emergency surgery

Interventions

DRUGPropofol

total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.

DRUGSevoflurane

The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).


Locations(1)

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05331911


Related Trials